This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Adam's Most Recent Article

MannKind Afrezza Sales Underwhelming Again, Sanofi Reports

07/30/15 - 11:03 AM EDT

The only saving grace is that no one, not even the most Kool-Aid-drinking MannKind supporter, is surprised by Afrezza's poor sales.

read more >

Other Articles by Adam

Free Reports

Biotech Stock Mailbag: Alzheimer's Conference Preview, Why Stock Prices Sometimes Lie Biotech Stock Mailbag: Alzheimer's Conference Preview, Why Stock Prices Sometimes Lie

07/17/15 - 06:45 AM EDT

Biotech columnist Adam Feuerstein answers readers' questions about health care.

read more >
Thoughts, Appraisals, Lingering Questions From Celgene's $7 Receptos Buy Thoughts, Appraisals, Lingering Questions From Celgene's $7 Receptos Buy

07/15/15 - 09:45 AM EDT

Receptos' ozanimod is one of the most compelling late-stage assets in biotech, which makes Celgene's decision to buy it look smart.

read more >
Gilead Hep C Sales Under Investor Microscope as Earnings Near Gilead Hep C Sales Under Investor Microscope as Earnings Near

07/13/15 - 12:01 PM EDT

The total number of prescriptions written for Gilead Sciences hepatitis C drugs Sovaldi and Harvoni in the U.S. peaked in March and are now in a consistent downtrend.

read more >
Anacor Prescription Lotion Clears Skin Rash in Late-Stage Test Anacor Prescription Lotion Clears Skin Rash in Late-Stage Test

07/13/15 - 07:35 AM EDT

Anacor intends to seek U.S. approval for a skin rash lotion, crisaborole, in the first half of next year, based on data collected from studies.

read more >
Northwest Bio Shareholders May Have Been Undercut by CEO Northwest Bio Shareholders May Have Been Undercut by CEO

07/09/15 - 12:26 PM EDT

The loans negotiated by CEO Linda Powers to a private firm she controls doesn't appear to violate securities laws, but she may have breached fiduciary duty to Northwest Bio shareholders.

read more >
Previewing the Next Look at Biogen's Alzheimer's Drug Previewing the Next Look at Biogen's Alzheimer's Drug

07/09/15 - 10:31 AM EDT

On Saturday, July 18, Biogen will present updated results from a closely watched clinical trial involving its Alzheimer's drug candidate aducanumab (formerly known as BIIB037).

read more >
Blame Keryx Executives, Not Short Sellers, for Dismal Drug Launch, Sinking Stock Blame Keryx Executives, Not Short Sellers, for Dismal Drug Launch, Sinking Stock

07/07/15 - 07:43 AM EDT

Short sellers -- "manipulative" or otherwise -- are not responsible for Keryx's withering stock price. The problem is Auryxia, the company's kidney dialysis drug.

read more >
Horizon Goes Hostile With $3 Billion Takeout Offer for Depomed Horizon Goes Hostile With $3 Billion Takeout Offer for Depomed

07/07/15 - 07:29 AM EDT

Like other specialty pharmaceutical makers headquartered in tax-friendly countries, Horizon is buying growth.

read more >
Vertex Wins U.S. Approval for New Cystic Fibrosis Drug Vertex Wins U.S. Approval for New Cystic Fibrosis Drug

07/02/15 - 02:36 PM EDT

The newly approved Vertex pill, taken twice per day, is targeted at a genetic defect found in almost half of cystic fibrosis patients.

read more >
Biotech Stock Mailbag: Grading 2015 Biotech Predictions at the Halfway Point Biotech Stock Mailbag: Grading 2015 Biotech Predictions at the Halfway Point

07/02/15 - 12:54 PM EDT

Biotech columnist Adam Feuerstein answers readers' questions about health care.

read more >
Page 2 of 339
Top Rated Stocks Top Rated Funds Top Rated ETFs